Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

Accurate, rapid and reliable, fully automated MRI brainstem segmentation for application in multiple sclerosis and neurodegenerative diseases.

Sander L, Pezold S, Andermatt S, Amann M, Meier D, Wendebourg MJ, Sinnecker T, Radue EW, Naegelin Y, Granziera C, Kappos L, Wuerfel J, Cattin P, Schlaeger R; Alzheimer's Disease Neuroimaging Initiative.

Hum Brain Mapp. 2019 Oct 1;40(14):4091-4104. doi: 10.1002/hbm.24687. Epub 2019 Jun 17.

PMID:
31206931
2.

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide.

Sprenger T, Kappos L, Radue EW, Gaetano L, Mueller-Lenke N, Wuerfel J, Poole EM, Cavalier S.

Mult Scler. 2019 Jun 14:1352458519855722. doi: 10.1177/1352458519855722. [Epub ahead of print]

PMID:
31198103
3.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

4.

Automated Detection and Segmentation of Multiple Sclerosis Lesions Using Ultra-High-Field MP2RAGE.

Fartaria MJ, Sati P, Todea A, Radue EW, Rahmanzadeh R, OʼBrien K, Reich DS, Bach Cuadra M, Kober T, Granziera C.

Invest Radiol. 2019 Jun;54(6):356-364. doi: 10.1097/RLI.0000000000000551.

PMID:
30829941
5.

Clinical associations of T2-weighted lesion load and lesion location in small vessel disease: Insights from a large prospective cohort study.

Altermatt A, Gaetano L, Magon S, Bauer L, Feurer R, Gnahn H, Hartmann J, Seifert CL, Poppert H, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Neuroimage. 2019 Apr 1;189:727-733. doi: 10.1016/j.neuroimage.2019.01.052. Epub 2019 Jan 24.

PMID:
30685330
6.

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression.

Nakamura Y, Gaetano L, Matsushita T, Anna A, Sprenger T, Radue EW, Wuerfel J, Bauer L, Amann M, Shinoda K, Isobe N, Yamasaki R, Saida T, Kappos L, Kira JI.

J Neuroinflammation. 2018 Sep 5;15(1):255. doi: 10.1186/s12974-018-1295-1.

7.

MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.

Bendfeldt K, Taschler B, Gaetano L, Madoerin P, Kuster P, Mueller-Lenke N, Amann M, Vrenken H, Wottschel V, Barkhof F, Borgwardt S, Klöppel S, Wicklein EM, Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Pohl C, Sandbrink R, Sprenger T, Radue EW, Wuerfel J, Nichols TE.

Brain Imaging Behav. 2019 Oct;13(5):1361-1374. doi: 10.1007/s11682-018-9942-9.

PMID:
30155789
8.

Clinical Correlations of Brain Lesion Location in Multiple Sclerosis: Voxel-Based Analysis of a Large Clinical Trial Dataset.

Altermatt A, Gaetano L, Magon S, Häring DA, Tomic D, Wuerfel J, Radue EW, Kappos L, Sprenger T.

Brain Topogr. 2018 Sep;31(5):886-894. doi: 10.1007/s10548-018-0652-9. Epub 2018 May 29.

PMID:
29845492
9.

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.

Gaetano L, Häring DA, Radue EW, Mueller-Lenke N, Thakur A, Tomic D, Kappos L, Sprenger T.

Neurology. 2018 Apr 10;90(15):e1324-e1332. doi: 10.1212/WNL.0000000000005292. Epub 2018 Mar 14.

PMID:
29540589
10.

A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo.

Vermersch P, Radue EW, Putzki N, Ritter S, Merschhemke M, Freedman MS.

Mult Scler J Exp Transl Clin. 2017 Sep 27;3(3):2055217317730096. doi: 10.1177/2055217317730096. eCollection 2017 Jul-Sep.

11.

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA.

Radue EW, Sprenger T, Gaetano L, Mueller-Lenke N, Cavalier S, Thangavelu K, Panzara MA, Donaldson JE, Woodward FM, Wuerfel J, Wolinsky JS, Kappos L.

Neurol Neuroimmunol Neuroinflamm. 2017 Aug 9;4(5):e390. doi: 10.1212/NXI.0000000000000390. eCollection 2017 Sep.

12.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

13.

Tracking the Evolution of Cerebral Gadolinium-Enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline.

Andermatt S, Papadopoulou A, Radue EW, Sprenger T, Cattin P.

J Neuroimaging. 2017 Sep;27(5):469-475. doi: 10.1111/jon.12439. Epub 2017 Mar 30.

PMID:
28370651
14.

Introduction to Magnetic Resonance Imaging for Neurologists.

Radue EW, Weigel M, Wiest R, Urbach H.

Continuum (Minneap Minn). 2016 Oct;22(5, Neuroimaging):1379-1398. Review.

15.

Striatal functional connectivity changes following specific balance training in elderly people: MRI results of a randomized controlled pilot study.

Magon S, Donath L, Gaetano L, Thoeni A, Radue EW, Faude O, Sprenger T.

Gait Posture. 2016 Sep;49:334-339. doi: 10.1016/j.gaitpost.2016.07.016. Epub 2016 Jul 19.

PMID:
27479219
16.

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J.

BMC Neurol. 2016 Jul 26;16:117. doi: 10.1186/s12883-016-0635-y.

17.

Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.

Sormani MP, Kappos L, Radue EW, Cohen J, Barkhof F, Sprenger T, Piani Meier D, Häring D, Tomic D, De Stefano N.

Mult Scler. 2017 Apr;23(5):656-664. doi: 10.1177/1352458516659550. Epub 2016 Jul 18.

PMID:
27411701
18.

Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.

De Stefano N, Tomic D, Radue EW, Sprenger T, Meier DP, Häring D, Sormani MP.

Mult Scler Relat Disord. 2016 May;7:98-101. doi: 10.1016/j.msard.2016.03.017. Epub 2016 Mar 31.

PMID:
27237768
19.

Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).

Amann M, Pezold S, Naegelin Y, Fundana K, Andělová M, Weier K, Stippich C, Kappos L, Radue EW, Cattin P, Sprenger T.

J Neurol. 2016 Jul;263(7):1364-74. doi: 10.1007/s00415-016-8133-0. Epub 2016 May 9.

PMID:
27159989
20.

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.

Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, Ramseier S, Achtnichts L, Findling O, Nedeltchev K, Radue EW, Sprenger T, Stippich C, Derfuss T, Louvion JF, Kamm CP, Mattle HP, Lotter C, Du Pasquier R, Schluep M, Pot C, Lalive PH, Yaldizli Ö, Gobbi C, Kappos L, Kuhle J; SMSC Scientific Board.

PLoS One. 2016 Mar 31;11(3):e0152347. doi: 10.1371/journal.pone.0152347. eCollection 2016.

21.

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.

Radue EW, Sprenger T, Vollmer T, Giovannoni G, Gold R, Havrdova E, Selmaj K, Stefoski D, You X, Elkins J.

Eur J Neurol. 2016 Feb;23(2):412-5. doi: 10.1111/ene.12922.

PMID:
26806217
22.

The association between olfactory bulb volume, cognitive dysfunction, physical disability and depression in multiple sclerosis.

Yaldizli Ö, Penner IK, Yonekawa T, Naegelin Y, Kuhle J, Pardini M, Chard DT, Stippich C, Kira JI, Bendfeldt K, Amann M, Radue EW, Kappos L, Sprenger T.

Eur J Neurol. 2016 Mar;23(3):510-9. doi: 10.1111/ene.12891. Epub 2015 Nov 19.

PMID:
26699999
23.

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.

Kappos L, Radue EW, Chin P, Ritter S, Tomic D, Lublin F.

J Neurol. 2016 Feb;263(2):354-360. doi: 10.1007/s00415-015-7978-y. Epub 2015 Dec 8.

24.

Classifying individuals at high-risk for psychosis based on functional brain activity during working memory processing.

Bendfeldt K, Smieskova R, Koutsouleris N, Klöppel S, Schmidt A, Walter A, Harrisberger F, Wrege J, Simon A, Taschler B, Nichols T, Riecher-Rössler A, Lang UE, Radue EW, Borgwardt S.

Neuroimage Clin. 2015 Sep 30;9:555-63. doi: 10.1016/j.nicl.2015.09.015. eCollection 2015.

25.

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.

Kappos L, De Stefano N, Freedman MS, Cree BA, Radue EW, Sprenger T, Sormani MP, Smith T, Häring DA, Piani Meier D, Tomic D.

Mult Scler. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19.

26.

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Jeffery DR, Di Cantogno EV, Ritter S, Meier DP, Radue EW, Camu W.

J Neurol. 2016 Feb;263(2):299-305. doi: 10.1007/s00415-015-7959-1. Epub 2015 Nov 14.

PMID:
26568562
27.

Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.

Traboulsee A, Simon JH, Stone L, Fisher E, Jones DE, Malhotra A, Newsome SD, Oh J, Reich DS, Richert N, Rammohan K, Khan O, Radue EW, Ford C, Halper J, Li D.

AJNR Am J Neuroradiol. 2016 Mar;37(3):394-401. doi: 10.3174/ajnr.A4539. Epub 2015 Nov 12.

28.

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A.

Neurology. 2015 Nov 10;85(19):1694-701. doi: 10.1212/WNL.0000000000002099. Epub 2015 Oct 9.

29.

Abnormal functional integration of thalamic low frequency oscillation in the BOLD signal after acute heroin treatment.

Denier N, Schmidt A, Gerber H, Vogel M, Huber CG, Lang UE, Riecher-Rossler A, Wiesbeck GA, Radue EW, Walter M, Borgwardt S.

Hum Brain Mapp. 2015 Dec;36(12):5287-300. doi: 10.1002/hbm.23011. Epub 2015 Oct 6.

PMID:
26441146
30.

Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.

Constantinescu CS, Asher A, Fryze W, Kozubski W, Wagner F, Aram J, Tanasescu R, Korolkiewicz RP, Dirnberger-Hertweck M, Steidl S, Libretto SE, Sprenger T, Radue EW.

Neurol Neuroimmunol Neuroinflamm. 2015 May 21;2(4):e117. doi: 10.1212/NXI.0000000000000117. eCollection 2015 Aug.

31.

Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication.

Bernasconi R, Smieskova R, Schmidt A, Harrisberger F, Raschle NM, Lenz C, Walter A, Simon A, Riecher-Rössler A, Radue EW, Lang UE, Fusar-Poli P, Borgwardt SJ.

Neuroimage Clin. 2015 Apr 29;8:230-7. doi: 10.1016/j.nicl.2015.04.016. eCollection 2015.

32.

Age of second language acquisition in multilinguals has an impact on gray matter volume in language-associated brain areas.

Kaiser A, Eppenberger LS, Smieskova R, Borgwardt S, Kuenzli E, Radue EW, Nitsch C, Bendfeldt K.

Front Psychol. 2015 Jun 8;6:638. doi: 10.3389/fpsyg.2015.00638. eCollection 2015.

33.

Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis.

Amann M, Papadopoulou A, Andelova M, Magon S, Mueller-Lenke N, Naegelin Y, Stippich C, Radue EW, Bieri O, Kappos L, Sprenger T.

J Neurol. 2015 Aug;262(8):1909-17. doi: 10.1007/s00415-015-7793-5. Epub 2015 Jun 5.

PMID:
26041614
34.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

35.

MRI characteristics of periaqueductal lesions in multiple sclerosis.

Papadopoulou A, Naegelin Y, Weier K, Amann M, Hirsch J, von Felten S, Yaldizli O, Sprenger T, Radue EW, Kappos L, Gass A.

Mult Scler Relat Disord. 2014 Jul;3(4):542-51. doi: 10.1016/j.msard.2014.01.001. Epub 2014 Jan 18.

PMID:
25877067
36.

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.

Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A, Radue EW, Giovannoni G, Kappos L.

Neurology. 2015 Apr 21;84(16):1639-43. doi: 10.1212/WNL.0000000000001491. Epub 2015 Mar 25.

37.

Increased functional connectivity in the resting-state basal ganglia network after acute heroin substitution.

Schmidt A, Denier N, Magon S, Radue EW, Huber CG, Riecher-Rossler A, Wiesbeck GA, Lang UE, Borgwardt S, Walter M.

Transl Psychiatry. 2015 Mar 24;5:e533. doi: 10.1038/tp.2015.28.

38.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.

Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

39.

Imaging of Primary Brain Tumors and Metastases with Fast Quantitative 3-Dimensional Magnetization Transfer.

Garcia M, Gloor M, Bieri O, Radue EW, Lieb JM, Cordier D, Stippich C.

J Neuroimaging. 2015 Nov-Dec;25(6):1007-14. doi: 10.1111/jon.12222. Epub 2015 Feb 20.

PMID:
25702714
40.

Fingolimod effect on brain volume loss independently contributes to its effect on disability.

Sormani MP, De Stefano N, Francis G, Sprenger T, Chin P, Radue EW, Kappos L.

Mult Scler. 2015 Jun;21(7):916-24. doi: 10.1177/1352458515569099. Epub 2015 Feb 6.

PMID:
25662353
41.

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.

Radue EW, Barkhof F, Kappos L, Sprenger T, Häring DA, de Vera A, von Rosenstiel P, Bright JR, Francis G, Cohen JA.

Neurology. 2015 Feb 24;84(8):784-93. doi: 10.1212/WNL.0000000000001281. Epub 2015 Jan 28.

42.

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).

Amann M, Andělová M, Pfister A, Mueller-Lenke N, Traud S, Reinhardt J, Magon S, Bendfeldt K, Kappos L, Radue EW, Stippich C, Sprenger T.

Neuroimage Clin. 2014 Nov 18;7:43-52. doi: 10.1016/j.nicl.2014.11.010. eCollection 2015.

43.

Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations.

Amann M, Sprenger T, Naegelin Y, Reinhardt J, Kuster P, Hirsch JG, Kappos L, Radue EW, Stippich C, Bieri O.

Neuroimage. 2015 Mar;108:87-94. doi: 10.1016/j.neuroimage.2014.12.045. Epub 2014 Dec 20.

PMID:
25536494
44.

The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls.

Weier K, Eshaghi A, Magon S, Andelova M, Radue EW, Kappos L, Azimi AR, Sahraian MA, Sprenger T.

Mult Scler. 2015 May;21(6):757-66. doi: 10.1177/1352458514554051. Epub 2014 Dec 5.

PMID:
25480863
45.

Reduced volume of the nucleus accumbens in heroin addiction.

Seifert CL, Magon S, Sprenger T, Lang UE, Huber CG, Denier N, Vogel M, Schmidt A, Radue EW, Borgwardt S, Walter M.

Eur Arch Psychiatry Clin Neurosci. 2015 Dec;265(8):637-45. doi: 10.1007/s00406-014-0564-y. Epub 2014 Dec 3.

PMID:
25467383
46.

Association of cognitive impairment and lesion volumes in multiple sclerosis--a MRI study.

Yildiz M, Tettenborn B, Radue EW, Bendfeldt K, Borgwardt S.

Clin Neurol Neurosurg. 2014 Dec;127:54-8. doi: 10.1016/j.clineuro.2014.09.019. Epub 2014 Oct 14.

PMID:
25459243
47.

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study.

Magon S, Gaetano L, Chakravarty MM, Lerch JP, Naegelin Y, Stippich C, Kappos L, Radue EW, Sprenger T.

BMC Neurosci. 2014 Sep 8;15:106. doi: 10.1186/1471-2202-15-106.

48.

Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.

Lukas C, Knol DL, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Weier K, Radue EW, Gass A, Kappos L, Naegelin Y, Uitdehaag BM, Geurts JJ, Barkhof F, Vrenken H.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):410-8. doi: 10.1136/jnnp-2014-308021. Epub 2014 Jun 27.

PMID:
24973341
49.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
50.

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21.

Supplemental Content

Loading ...
Support Center